Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
MWN-AI** Summary
Windtree Therapeutics, Inc. has made significant strides in the production of PHEXXI, a hormone-free contraceptive gel developed by Evofem Biosciences. A recent contract with a pharmaceutical manufacturer in China aims to reduce manufacturing costs for PHEXXI by over 50% by the end of 2026. This agreement, effective since March 2025, marks a pivotal partnership that highlights Windtree’s commitment to enhancing cost-efficiency and ensuring sustainability in production.
Currently, the tech transfer process is in progress, with validation batch manufacturing expected to commence in 2026. Windtree’s CEO, Jed Latkin, expressed optimism about the collaboration, citing the potential for revenue generation as early as 2026. PHEXXI stands out as a first-in-class vaginal gel that empowers women with on-demand contraceptive control.
Evofem has reported consistent growth in PHEXXI sales, turning in its fourth consecutive year of net sales increases in 2024. The company is also expanding its global reach, having submitted marketing applications for PHEXXI in the United Arab Emirates, set for potential approval in early 2026—marking Evofem's first international foray outside the U.S.
Windtree's partnership with Evofem, established under a License and Supply Agreement, showcases their strategic approach to become a revenue-generating entity across various sectors. This collaboration not only positions Windtree to benefit financially but also enhances the availability and accessibility of innovative contraceptive options in a competitive market.
The agreement aligns well with Windtree's broader strategy to drive profitability while navigating the complexities of pharmaceutical manufacturing, regulatory challenges, and global market demands.
MWN-AI** Analysis
Windtree Therapeutics (Nasdaq: WINT) has announced significant advancements in the manufacturing of PHEXXI, Evofem's hormone-free contraceptive gel, with a strategic agreement that is poised to reduce production costs by over 50% by the end of 2026. This partnership with a Chinese manufacturer signals a critical shift for both companies, promising potential revenue growth while enhancing the product's market competitiveness.
Windtree's adept handling of tech transfer processes and validation batch manufacturing is key to realizing these cost reductions. The anticipated revenue generation starting in 2026 could enhance Windtree’s long-term financial stability and contribute positively to its stock performance. Investors should closely watch the company’s progress in implementing these manufacturing efficiencies and the outcomes of its tech transfer, as successful execution is vital to the anticipated financial uplift.
Furthermore, the continued sales growth of PHEXXI, highlighted by Evofem’s performance in 2024, shows strong market validation and consumer acceptance. As Evofem prepares for an international market rollout, particularly the submission for marketing approval in the UAE, there is potential for revenue diversification. This expansion can bolster both companies' revenues, especially as they explore additional partnerships.
It's also essential for investors to consider the underlying risks mentioned, including execution challenges and regulatory hurdles that could impact timelines and operational efficiency. The geopolitical climate’s effect on international supply chains adds an additional layer of complexity that could influence Windtree's operations.
In summary, Windtree's proactive cost-management strategy paired with Evofem’s market expansion plans offers a favorable outlook for stakeholders. Investors may find opportunities in Windtree's evolving landscape, but they should remain cautious of the inherent uncertainties and monitor developments closely in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement
Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026
Tech transfer underway with validation batch manufacturing expected to begin in 2026
Evofem and Windtree exploring other partnerships
WARRINGTON, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (Nasdaq: WINT) today announced that it has contracted with a pharmaceutical manufacturer in China to produce Evofem’s hormone-free contraceptive product, PHEXXI ® (lactic acid, citric acid and potassium bitartrate) , at a cost that is significantly below current levels.
With the tech transfer process now underway, and early-stage manufacturing expected to begin later this year, Windtree anticipates the arrangement will generate revenue for Windtree, while reducing Evofem’s cost to manufacture the PHEXXI by more than 50% by year end 2026.
“Since becoming Evofem’s sourcing partner for PHEXXI in March 2025, we have made rapid and significant progress,” said Jed Latkin, CEO of Windtree Therapeutics. “With this manufacturing contract inked and tech transfer underway for PHEXXI, we believe this arrangement will begin to generate revenue for Windtree in 2026.”
PHEXXI is a first-in-class, hormone-free, prescription contraceptive vaginal gel that women control. Evofem delivered its fourth consecutive year of PHEXXI net sales growth in 2024 and is poised to enter its first market outside the United States in early 2026; Evofem’s licensee Pharma 1 Drug Store, LLC, submitted PHEXXI for marketing approval in the United Arab Emirates in June 2025.
Windtree serves as Evofem’s sourcing partner for PHEXXI under the company’s March 2025 License and Supply Agreement.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company focused on becoming a revenue generating company in a multitude of growing industries to drive toward overall profitability. Learn more at www.windtreetx.com .
PHEXXI ® is a registered trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the ability of the contracted manufacturer to timely complete the tech transfer process for PHEXXI; the successful manufacture of validation batches that meet FDA specifications and gain FDA approval; the Company’s ability to continue to reduce manufacturing costs; the Company’s risks and uncertainties associated with the success and advancement of its product candidates; the Company’s ability to manage costs and execute on its operational and budget plans; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to regulatory requirements; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the impacts of political unrest, including as a result of geopolitical tension, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Information
Windtree Therapeutics, Inc.
Eric Curtis
ecurtis@windtreetx.com
FAQ**
How does Windtree Therapeutics Inc. WINT plan to manage the risks associated with the tech transfer process and ensure timely completion of PHEXXI validation batch manufacturing by 2026?
What other potential partnerships are Windtree Therapeutics Inc. WINT exploring to further enhance the commercialization of PHEXXI and reduce manufacturing costs beyond the 50% target?
What measures are in place to mitigate potential geopolitical tensions affecting Windtree Therapeutics Inc. WINT's supply chain and operations in light of this new manufacturing agreement with a Chinese company?
With Evofem's PHEXXI poised to enter international markets, how does Windtree Therapeutics Inc. WINT plan to develop its sales and marketing capabilities to support this expansion effectively?
**MWN-AI FAQ is based on asking OpenAI questions about Windtree Therapeutics Inc. (NASDAQ: WINT).
NASDAQ: WINT
WINT Trading
-12.12% G/L:
$0.116 Last:
1,921,610 Volume:
$0.132 Open:
